Zobrazeno 1 - 10
of 48
pro vyhledávání: ''
Autor:
Zobair M. Younossi, Marc Bourliere, Linda Henry, Christophe Hézode, T. Asselah, Philippe Mathurin, Victor de Ledinghen, Maria Stepanova, Patrice Cacoub
Publikováno v:
Value in Health. 21:1218-1225
In addition to high efficacy, new anti-hepatitis C virus (HCV) regimens improve patient-reported outcomes (PROs), which must be considered by policymakers in different countries when deciding upon treatment coverage.To assess PROs of French patients
Publikováno v:
Value in Health. 24:S95-S96
Publikováno v:
Value in Health. 20:1110-1120
To evaluate the cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR) regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3D ± RBV), and sofosbuvir/velpatasvir (SOF/VEL) in pati
Publikováno v:
Value in Health. 22:S851
Autor:
J.S. Yoon, N. Grunow, C. López López, Tatsuya Yamashita, Laetitia Fartoux, Arndt Vogel, Stacie Hudgens, Shukui Qin, Krzysztof Simon, Silvija Kraljevic, Masatoshi Kudo, Toshiyuki Tamai, Genevieve Meier, Max W. Sung, V. Breder, Corina E. Dutcus
Publikováno v:
Value in Health. 20:A454-A455
Publikováno v:
Value in Health. 20:A893-A894
Publikováno v:
Value in Health. 21:S295
Publikováno v:
Value in Health. 21:S119
Publikováno v:
Value in Health. 21:S453
Publikováno v:
Value in Health. 18(7)